Overview
- The companies announced a co-development deal with a 50/50 split of costs and profits that includes a $40 million upfront payment from Regeneron for four initial therapy programs.
- Regeneron holds an option to add four more programs beyond the initial slate, which would trigger additional upfront payments.
- Telix can opt out of co-funding any program in exchange for up to $535 million in development and commercial milestones per program plus low double-digit royalties, with aggregate milestones across the deal reaching up to $2.1 billion.
- The collaboration pairs Regeneron’s antibody platforms, including VelocImmune and bispecifics, with Telix’s radiopharma manufacturing network to create drugs that carry a radioactive payload to cancer cells while sparing more healthy tissue.
- The partners will also build imaging tools to select patients and track response, with Telix leading commercialization and Regeneron receiving a share of profits, and they did not announce trial start dates or regulatory filings.